poisar

Stock

TScan Therapeutics, Inc. TCRX

$0.74-1.93%

Overview

TCRX market data

Price History

TCRX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.00
Diluted earnings per share over the trailing twelve months.
Beta
1.13
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.73 – $2.57
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $49.4 · P/B 0.46 · P/S 5.41.

Company News

7 captured
TScan Therapeutics Announces First Patient Infused With TSC-101 In Pivotal Phase 3 ALLOHA-2 Trial For AML, MDS Relapse Prevention After TransplantBenzinga · Jul 29, 2026, 11:06 AM
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price TargetBenzinga · Jun 23, 2026, 12:25 PM
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price TargetBenzinga · Jun 23, 2026, 11:50 AM
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationGlobenewswire Inc · Jun 22, 2026, 11:15 AM
TScan Says Cancer Therapy Data Support Move to Phase 3 TrialBenzinga · Jun 22, 2026, 11:10 AM
8-K filing — TScan Therapeutics, Inc. (TCRX)SEC EDGAR · Jun 22, 2026, 11:09 AM
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobenewswire Inc · May 6, 2026, 11:05 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock